Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
31 Leser
Artikel bewerten:
(0)

Covance Recognized for Outstanding Performance by Merck & Co., Inc.

PRINCETON, N.J., July 31 /PRNewswire-FirstCall/ -- Covance Inc. , a leading provider of drug development services, today announced that its central laboratory services received Merck & Co., Inc.'s Outstanding Strategic Collaboration Award.

Covance Central Laboratory Services is one of only 12 suppliers who were selected from thousands of Merck suppliers. The criteria for receiving this award included scorecard performance; contributions towards the Key Business Result (KBR) for Merck; Covance's ability to work with niche suppliers to further Merck's business; and operational excellence. Covance received the award at Merck's annual Supplier Recognition Forum.

"Our strategy of operational and service excellence is critical to our success. We are proud of our Merck team for delivering on this strategy and of the work that we all have done with Merck as well as the positive impact it has had on human lives," said Deborah Tanner, President of Covance Central Laboratory Services and Senior Vice President of Covance Inc. "We are honored to be recognized for the collaborative spirit, innovation, expertise, experience, and integrity we bring to our partnerships."

Covance is the most experienced central laboratory services provider in the world. Since 1986, it has focused solely on clinical trials. In the past five years alone, it has performed more than 150 million tests; provided services for more than 3,000 clinical trial protocols; and supported nearly 100,000 investigator sites in 100 countries. It maintains wholly-owned central laboratories in Indianapolis, Indiana; Geneva, Switzerland; Singapore; and Shanghai, China.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and nearly 9,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com/.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2008 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.